| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2022 | 13.26% | Barrington Research | → $31 | Upgrades | Market Perform → Outperform |
| 10/14/2022 | -5.01% | Stephens & Co. | → $26 | Reinstates | → Equal-Weight |
| 03/09/2022 | — | Stephens & Co. | Downgrades | Overweight → Equal-Weight | |
| 11/16/2021 | 100.95% | Stephens & Co. | → $55 | Initiates Coverage On | → Overweight |
| 07/16/2021 | 68.07% | UBS | → $46 | Initiates Coverage On | → Neutral |
| 12/16/2020 | 57.11% | Barrington Research | → $43 | Upgrades | Market Perform → Outperform |
| 01/21/2020 | 122.87% | Sidoti & Co. | → $61 | Upgrades | Neutral → Buy |
| 11/05/2019 | 5.96% | BWS Financial | → $29 | Initiates Coverage On | → Sell |
| 09/23/2019 | — | First Analysis | Downgrades | Strong Buy → Outperform | |
| 02/22/2019 | 49.8% | Sidoti & Co. | $56 → $41 | Downgrades | Buy → Neutral |
| 07/27/2018 | — | Barrington Research | Upgrades | Market Perform → Outperform | |
| 06/20/2018 | 24.22% | First Analysis | $45 → $34 | Downgrades | Overweight → Equal-Weight |
| 05/04/2018 | — | Barrington Research | Upgrades | Market Perform → Outperform | |
| 02/23/2018 | — | Barrington Research | Downgrades | Outperform → Market Perform | |
| 01/24/2018 | — | First Analysis | Upgrades | Equal-Weight → Overweight |
Anika Therapeutics Questions & Answers
The latest price target for Anika Therapeutics (NASDAQ: ANIK) was reported by Barrington Research on November 9, 2022. The analyst firm set a price target for $31.00 expecting ANIK to rise to within 12 months (a possible 13.26% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Anika Therapeutics (NASDAQ: ANIK) was provided by Barrington Research, and Anika Therapeutics upgraded their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on November 9, 2022 so you should expect the next rating to be made available sometime around November 9, 2023.
While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a upgraded with a price target of $0.00 to $31.00. The current price Anika Therapeutics (ANIK) is trading at is $27.37, which is within the analyst's predicted range.